Virus infections in tumors pave the way for tumor-directed DC-vaccines

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 208-210

  Woller, Norman ^a   Kühnel, Florian ^a   Kubicka, Stefan ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Kreiskliniken Reutlingen   (Germany)

Author keywords

DC vaccination; Immunotherapy; Oncolysis; Tumor; Virotherapy

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; PEXASTIMOGENE DEVACIREPVEC; SIPULEUCEL T; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; NOTE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE TUMOR; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; TUMOR VIRUS; VIRAL CLEARANCE; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84886945382     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18099     Document Type: Note

References (10)

1. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009; 9:1163-76; http://dx.doi.org/10.1517/14712590903170653
2. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multimechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477:99-102; http://dx.doi.org/10.1038/nature10358
3. Prestwich RJ, Errington F, Diaz RM, Pandha H, Harrington KJ, Melcher AA, et al. The Case of Oncolytic Viruses vs The Immune System: Waiting On The Judgment of Solomon. Hum Gene Ther 2009; 20:1119-32; http://dx.doi.org/10.1089/hum.2009.135
4. Woller N, Knocke S, Mundt B, Gurlevik E, Struver N, Kloos A, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011; 121:2570-82; http://dx.doi.org/10.1172/JCI45585
5. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008; 320: 1220-4; http://dx.doi.org/10.1126/science.1155209
6. Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support crosspresentation and CD8(+) T cell priming in naive mice. Immunity 2010; 33:942-54; http://dx.doi.org/10.1016/j.immuni.2010.11.022
7. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 18:1430-9; http://dx.doi.org/10.1038/mt.2010.98
8. Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 2011; 17: 854-9; http://dx.doi.org/10.1038/nm.2390
9. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; http://dx.doi.org/10.1038/nm1622
10. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; http://dx.doi.org/10.1038/nm.2438